1
|
Zou Y, Gutierrez O, Sader AC, Patel ND, Fandrick DR, Busacca CA, Fandrick KR, Kozlowski M, Senanayake CH. A Computational Investigation of the Ligand-Controlled Cu-Catalyzed Site-Selective Propargylation and Allenylation of Carbonyl Compounds. Org Lett 2017; 19:6064-6067. [PMID: 29095633 PMCID: PMC5718194 DOI: 10.1021/acs.orglett.7b02845] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
![]()
A copper-catalyzed
site-selective propargylation/allenylation reaction
toward carbonyl compounds has been mechanistically investigated using
a computational approach. Different reaction pathways and catalytic
cycles were investigated. Control of the site selectivity arises from
a destabilizing interaction introduced by the phenyl-substituted ligand.
Collapse
Affiliation(s)
- Yike Zou
- Department of Chemistry, Roy and Diana Vagelos Laboratories, University of Pennsylvania , Philadelphia, Pennsylvania 19104, United States
| | - Osvaldo Gutierrez
- Department of Chemistry, Roy and Diana Vagelos Laboratories, University of Pennsylvania , Philadelphia, Pennsylvania 19104, United States
| | - Avery C Sader
- Department of Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc. , 900 Ridgebury Road, Ridgefield, Connecticut 06778, United States
| | - Nitinchandra D Patel
- Department of Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc. , 900 Ridgebury Road, Ridgefield, Connecticut 06778, United States
| | - Daniel R Fandrick
- Department of Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc. , 900 Ridgebury Road, Ridgefield, Connecticut 06778, United States
| | - Carl A Busacca
- Department of Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc. , 900 Ridgebury Road, Ridgefield, Connecticut 06778, United States
| | - Keith R Fandrick
- Department of Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc. , 900 Ridgebury Road, Ridgefield, Connecticut 06778, United States
| | - Marisa Kozlowski
- Department of Chemistry, Roy and Diana Vagelos Laboratories, University of Pennsylvania , Philadelphia, Pennsylvania 19104, United States
| | - Chris H Senanayake
- Department of Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc. , 900 Ridgebury Road, Ridgefield, Connecticut 06778, United States
| |
Collapse
|
2
|
Affiliation(s)
- Paul A. Hume
- School of Chemical Sciences, The University of Auckland, 23 Symonds Street, Auckland, New Zealand
| | - Daniel P. Furkert
- School of Chemical Sciences, The University of Auckland, 23 Symonds Street, Auckland, New Zealand
| | - Margaret A. Brimble
- School of Chemical Sciences, The University of Auckland, 23 Symonds Street, Auckland, New Zealand
| |
Collapse
|
3
|
Fandrick KR, Ogikubo J, Fandrick DR, Patel ND, Saha J, Lee H, Ma S, Grinberg N, Busacca CA, Senanayake CH. Copper-Catalyst-Controlled Site-Selective Allenylation of Ketones and Aldehydes with Propargyl Boronates. Org Lett 2013; 15:1214-7. [DOI: 10.1021/ol400124f] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Keith R. Fandrick
- Chemical Development, Boehringer-Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877-0368, United States
| | - Junichi Ogikubo
- Chemical Development, Boehringer-Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877-0368, United States
| | - Daniel R. Fandrick
- Chemical Development, Boehringer-Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877-0368, United States
| | - Nitinchandra D. Patel
- Chemical Development, Boehringer-Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877-0368, United States
| | - Jaideep Saha
- Chemical Development, Boehringer-Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877-0368, United States
| | - Heewon Lee
- Chemical Development, Boehringer-Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877-0368, United States
| | - Shengli Ma
- Chemical Development, Boehringer-Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877-0368, United States
| | - Nelu Grinberg
- Chemical Development, Boehringer-Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877-0368, United States
| | - Carl A. Busacca
- Chemical Development, Boehringer-Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877-0368, United States
| | - Chris H. Senanayake
- Chemical Development, Boehringer-Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877-0368, United States
| |
Collapse
|
4
|
Affiliation(s)
- Yan Zou
- Department of Chemistry, North Carolina State University, Raleigh, North Carolina 27695
| | - Alexander Deiters
- Department of Chemistry, North Carolina State University, Raleigh, North Carolina 27695
| |
Collapse
|
5
|
Lee JT, Chen DY, Yang Z, Ramos AD, Hsieh JJD, Bogyo M. Design, syntheses, and evaluation of Taspase1 inhibitors. Bioorg Med Chem Lett 2009; 19:5086-90. [PMID: 19631530 PMCID: PMC3513416 DOI: 10.1016/j.bmcl.2009.07.045] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2009] [Revised: 06/20/2009] [Accepted: 07/02/2009] [Indexed: 12/14/2022]
Abstract
Taspase1 is a threonine protease responsible for cleaving MLL (Mixed-Lineage Leukemia) to achieve proper HOX gene expression. Subsequent studies identified additional Taspase1 substrates including Transcription Factor IIA (TFIIA) and Drosophila HCF. Taspase1 is essential for cell proliferation and is overexpressed in many cancer cell lines. Currently no small molecule inhibitors of this enzyme have been described. Here, we report the synthesis and evaluation of vinyl sulfone, vinyl ketone, epoxy ketone, and boronic acid inhibitors designed based on the preferred Taspase1 cleavage site (Ac-Ile-Ser-Gln-Leu-Asp). Specifically, we evaluated compounds in which the reactive warhead is positioned in place of the P1 aspartic acid side chain as well as at the C-terminus of the peptide. Interestingly, both classes of inhibitors were effective and vinyl ketones and vinyl sulfones showed the greatest potency for the target protease. These results suggest that Taspase1 has unique substrate recognition properties that could potentially be exploited in the design of potent and selective inhibitors of this enzyme.
Collapse
Affiliation(s)
- Jeong Tae Lee
- Department of Pathology, Stanford School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA
| | | | | | | | | | | |
Collapse
|